drugset / Trial / NCT03721900
Ketamine for Major Depressive Disorder
Non-randomizedSequentialSingle-blindTreatment
Summary
The purpose of this study is to measure the amount of ketamine in blood over time in subjects diagnosed with Major Depressive Disorder (MDD) and explore the anti-depressive effects of ketamine delivered by transdermal patch.
Timeline
- Start
- 2018-12-28
- Primary completion
- 2019-06-06
- Completion
- 2019-06-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketamine | Small molecule | 20 mg | Other |
| Subject | Ketamine | Small molecule | 40 mg | Other |